Targeting von Willebrand Factor in Ischaemic Stroke: Focus on Clinical Evidence.

Abstract excerpt

Despite great efforts in stroke research, disability and recurrence rates in ischaemic stroke remain unacceptably high. To address this issue, one potential target for novel therapeutics is the glycoprotein von Willebrand factor (vWF), which increases in thrombogenicity especially under high shear rates as it bridges between vascular sub-endothelial collagen and platelets. The rationale for vWF as a potential...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to ADAMTS13 Protein
• Share to Disease Models, Animal
• Share to Evidence-Based Medicine